

## Poolbeg Pharma plc

### Annual Report & AGM Notice

12 April 2023 - [Poolbeg Pharma](#) (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, confirms that the Company's Annual Report and Accounts for the period ended 31 December 2022 and the notice of Annual General Meeting ("AGM") 2022 have been posted to shareholders.

The 2022 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy are available to download from the Company's website: <https://www.poolbegpharma.com/investors/documents/>

The Annual General Meeting will be held at the offices of DAC Beachcroft LLP, 25 Walbrook, London EC4N 8AF, United Kingdom on 11 May 2023 at 12pm.

- Ends -

#### Enquiries

**Poolbeg Pharma Plc**  
Jeremy Skillington, CEO  
Ian O'Connell, CFO

+44 (0) 207 183 1499

**finnCap Ltd (Nominated Adviser & Joint Broker)**  
Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

+44 (0) 207 220 0500

**Singer Capital Markets (Joint Broker)**  
Phil Davies, Sam Butcher

+44 (0) 207 496 3000

**J&E Davy (Joint Broker)**  
Anthony Farrell, Niall Gilchrist

+353 (0) 1 679 6363

**Optimum Strategic Communications**  
Mary Clark, Nick Bastin, Vici Rabbatts

+44 (0) 208 078 4357  
[poolbeg@optimumcomms.com](mailto:poolbeg@optimumcomms.com)

#### About Poolbeg Pharma

Poolbeg Pharma specialises in the development of innovative medicines to address the unmet need in infectious and other prevalent diseases. Poolbeg has a disciplined portfolio approach to mitigate risk, accelerate drug development, and enhance investor returns. The Company simultaneously advances multiple programmes in cost-effective clinical trials, rapidly generating early human safety and efficacy data to enable early partnering / out-licensing, with the funds generated reinvested in the pipeline. Poolbeg also uses AI to interrogate human challenge trial data sets to quickly identify new targets and drugs, and in-license near or in the clinic medicines, leading to faster development and greater commercial appeal.

The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed \$250bn by 2025. Through opportunistic identification of assets which complement Poolbeg's existing pipeline, the Company is progressing programmes in oncology and metabolic syndromes; adding disease areas with significant addressable markets.

With its initial assets from [hVIVO plc](#) (formerly Open Orphan plc), an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza and other acute inflammatory conditions (POLB 001) which produces a highly significant reduction in p38

MAP kinase driven cytokines in a clinical setting; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The Company is also developing two Oral Delivery Programmes and is progressing two Artificial Intelligence (AI) Programmes to add promising new assets to its pipeline.

For more information, please go to [www.poolbegpharma.com](http://www.poolbegpharma.com) or follow us on [Twitter](#) and [LinkedIn](#) @PoolbegPharma.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAFLFFESIILLIV